Helius Medical Technologies Inc (HSDT)

[ALERTS100%to10000%GAIN]

great news here Helius Medical Technologies Inc. (HSDT) shares more than doubled premarket to 88 cents.
The neurotech company said results from independent research conducted at the University of Wisconsin-Madison on translingual neurostimulation for the treatment of chronic symptoms due to mild-to moderate traumatic brain injury were published in the December 2019 issue of the Archives of Rehabilitation Research and Clinical Translation.
The newly-published results from the double-blind randomized clinical trial which paired translingual neurostimulation using the Portable Neuromodulation Stimulator device with therapeutic activities, showed significantly improved balance and gait scores over the 14-week treatment period and the outcomes were sustained for 12 weeks after discontinuing the treatment, the company said.
The trial evaluated 43 participants. Researchers found about 74% of the participants who completed the 14 weeks of PoNS Treatment experienced significant improvements in their balance, the company said. Patients also showed meaningful improvements in their gait and walking endurance.

Write to Michael Dabaie at [e-mail]